Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Stong

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Clinical Genetics|October 19, 2023
The best of both worlds: Blending cutting-edge research with clinical processes for a productive exome clinicJennifer A Sullivan, Rebecca C Spillmann, Kelly Schoch, et al.
Cold Spring Harbor Molecular Case Studies|July 21, 2018
Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson diseaseJulia Wattacheril, Patrick R Shea, Saeed Mohammad, et al.
Blood|October 12, 2022
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaNaser Ansari-Pour, Mehmet Samur, Erin Flynt, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 17, 2018
A comprehensive iterative approach is highly effective in diagnosing individuals who are exome negativeVandana Shashi, Kelly Schoch, Rebecca Spillmann, et al.
The EMBO Journal|December 15, 2015
Subtelomeric p53 binding prevents accumulation of DNA damage at human telomeresStephen Tutton, Greggory A Azzam, Nicholas Stong, et al.
Genetics|April 6, 2022
Ancestry adjustment improves genome-wide estimates of regional intoleranceTristan J Hayeck, Nicholas Stong, Evan Baugh, et al.
British Journal of Haematology|July 16, 2025
Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myelomaNathan Martin, Ethan Thompson, Nicholas Stong, et al.
Cell Reports. Medicine|May 22, 2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myelomaMichael Amatangelo, Erin Flynt, Nicholas Stong, et al.
Genome Research|March 29, 2014
Subtelomeric CTCF and cohesin binding site organization using improved subtelomere assemblies and a novel annotation pipelineNicholas Stong, Zhong Deng, Ravi Gupta, et al.
Human Mutation|July 3, 2019
Heterozygous variants in MYBPC1 are associated with an expanded neuromuscular phenotype beyond arthrogryposisVandana Shashi, Janelle Geist, Youngha Lee, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Clinical Genetics|October 19, 2023
The best of both worlds: Blending cutting-edge research with clinical processes for a productive exome clinicJennifer A Sullivan, Rebecca C Spillmann, Kelly Schoch, et al.
Cold Spring Harbor Molecular Case Studies|July 21, 2018
Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson diseaseJulia Wattacheril, Patrick R Shea, Saeed Mohammad, et al.
Blood|October 12, 2022
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaNaser Ansari-Pour, Mehmet Samur, Erin Flynt, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 17, 2018
A comprehensive iterative approach is highly effective in diagnosing individuals who are exome negativeVandana Shashi, Kelly Schoch, Rebecca Spillmann, et al.
The EMBO Journal|December 15, 2015
Subtelomeric p53 binding prevents accumulation of DNA damage at human telomeresStephen Tutton, Greggory A Azzam, Nicholas Stong, et al.
Genetics|April 6, 2022
Ancestry adjustment improves genome-wide estimates of regional intoleranceTristan J Hayeck, Nicholas Stong, Evan Baugh, et al.
British Journal of Haematology|July 16, 2025
Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myelomaNathan Martin, Ethan Thompson, Nicholas Stong, et al.
Cell Reports. Medicine|May 22, 2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myelomaMichael Amatangelo, Erin Flynt, Nicholas Stong, et al.
Genome Research|March 29, 2014
Subtelomeric CTCF and cohesin binding site organization using improved subtelomere assemblies and a novel annotation pipelineNicholas Stong, Zhong Deng, Ravi Gupta, et al.
Human Mutation|July 3, 2019
Heterozygous variants in MYBPC1 are associated with an expanded neuromuscular phenotype beyond arthrogryposisVandana Shashi, Janelle Geist, Youngha Lee, et al.
Pageof 6